Study on the regulation of mRNA expression of GABA transporters (GAT-1 and GAT-3) in rat brain

The submitted work concentrated on the study of mRNA expression of two distinct GABA transporters, GAT-1 and GAT-3, in the rat brain. For the detection and quantification of the chosen mRNAs, appropriate methods had to be established. Two methods, ribonuclease protection assay (RPA) and competitive RT-PCR were emloyed in the present study. Competitive RT-PCR worked out to be 20 times more sensitive as RPA. Unlike the sensitivity, the fidelity of both techniques was comparable with respect to their intra- and inter-assay variability.The basal mRNA levels of GAT-1 and GAT-3 were measured in various brain regions. Messenger RNAs for both transporters were detected in all tested brain regions. Depending on the region, the observed mRNA level for GAT-1 was 100-300 higher than for GAT-3. The GAT-1 mRNA levels were similar in all tested regions. The distribution of GAT-3 mRNA seemed to be more region specific. The strongest GAT-3 mRNA expression was detected in striatum, medulla oblongata and thalamus. The lowest levels of GAT-3 were in cortex frontalis and cerebellum.Furthermore, the mRNA expression for GAT-1 and GAT-3 was analysed under altered physiological conditions; in kindling model of epilepsy and also after long-term treatment drugs modulating GABAergic transmission. In kindling model of epilepsy, altered GABA transporter function was hypothesised by During and coworkers (During et al., 1995) after observed decrease in binding of nipecotic acid, a GAT ligand, in hippocampus of kindled animals. In the present work, the mRNA levels were measured in hippocampus and whole brain samples. Neither GAT-1 nor GAT-3 showed altered transcription in any tested region of kindled animals compared to controls. This leads to conclusion that an altered functionality of GABA transporters is involved in epilepsy rather than a change in their expression.The levels of GAT-1 and GAT-3 mRNAs were also measured in the brain of rats chronically treated with diazepam or zolpidem, GABAA receptor agonists. Prior to the molecular biology tests, behavioural analysis was carried out with chronically and acutely treated animals. In two tests, open field and elevated plus-maze, the basal activity exploration and anxiety-like behaviour were analysed. Zolpidem treatment increased exploratory activity. There were observed no differencies between chronically and acutely treated animals. Diazepam increased exploratory activity and decresed anxiety-like behaviour when applied acutely. This effect disappeard after chronic administration of diazepam. The loss of effect suggested a development of tolerance to effects of diazepam following long-term administration. Double treatment, acute injection of diazepam after chronic diazepam treatment, confirmed development of a tolerance to effects of diazepam. Also, the mRNAs for GAT-1 and GAT-3 were analysed in cortex frontalis, hippocampus, cerebellum and whole brain samples of chronically treated animals. The mRNA levels for any of tested GABA transporters did not show significant changes in any of tested region neither after diazepam nor zolpidem treatment. Therefore, changes in GAT-1 and GAT-3 transcription are probably not involved in adaptation of GABAergic system to long-term benzodiazepine administration and so in development of tolerance to benzodiazepines.

Assessing the role of sCYLD and Bcl-3 in immune regulation

CYLD is a deubiquitinating enzyme, which negatively regulates NF-κB signaling by removing Lys63-linked polyubiquitin chains from its substrates. In mice, there are two variants of CYLD: full-length CYLD (FL-CYLD) and its short splice variant sCYLD. sCYLD lacks the NEMO and TRAF2 binding sites and CYLDex7/8 mice, which have been generated in our laboratory, overexpress sCYLD in the absence of the full length transcript. In this thesis, we show that bone marrow-derived macrophages (BMDCs) overexpressing sCYLD display a hyperactive phenotype. They have increased levels of the inflammatory cytokines IL-6 and TNFα, have exaggerated stimulatory capacity and fail to induce tolerance in in vivo experiments. CYLDex7/8 BMDCs have increased levels of nuclear Bcl-3, which we could show to be directly induced by sCYLD expression. NF-κB signaling was markedly upregulated in CYLDex7/8 BMDCs.rnBcl-3 overexpressing BMDCs with normal CYLD expression, however, were not hyperactive, suggesting that Bcl-3 overexpression is not sufficient for causing the observed phenotype. Taken together we propose a model in which the exclusive overexpression of sCYLD with high nuclear levels of Bcl-3 in BMDCs is accompanied by an increased NF-κB activation, resulting in a hyperactive phenotype.rnWe further analyzed macrophages overexpressing sCYLD using the LysMcre CyldFL/FL strain, but could not detect differences in activation marker expression, cytokine secretion or iNOS production. LysMcre CyldFL/FL mice immunized with MOG35-55 peptide showed a more severe course of experimental autoimmune encephalomyelitis (EAE), which could not be explained by enhanced levels of MHC class II on CNS-resident macrophages and microglia or increased T cell infiltration.rnMice overexpressing Bcl-3 in T cells develop spontaneous colitis. They have less peripheral memory/effector T cells and less Th1 cells, whereas Th17 numbers are normal. Naïve T cells overexpressing Bcl-3 show defects in in vitro differentiation to the Th1 or Th17 fate. CD4+ T cells overexpressing Bcl-3 show enhanced survival capacity in in vitro culture, but have a defect in proliferative capacity when stimulated in vitro or when adoptively transferred into lymphopenic hosts.

Atmospheric heterogeneous reactions of N 2 O 5 and NO 3 radicals with mineral dust particles

Die heterogenen Reaktionen von N2O5 bzw. NO3 auf mineralischen Staubpartikeln wurden untersucht, um deren Einfluss auf den Abbau atmosphärischer Stickoxide (NOx) sowie auf die chemische Veränderung der Staubpartikel während ihres Transportes durch die Atmosphäre besser verstehen zu können. Die experimentellen Studien wurden bei Atmosphärendruck, Raumtemperatur und unterschiedlichen relativen Luftfeuchten durchgeführt. Der Aufnahmekoeffizient γ(N2O5) von N2O5 auf dispergiertem Staub aus der Sahara wurde zu 0,020 ± 0,002 (1σ) bestimmt, unabhängig von der relativen Feuchte (0 - 67 %) sowie der N2O5-Konzentration (5x1011 - 3x1013 Moleküle cm-3).rnDie Analyse der Reaktionsprodukte in der Gasphase sowie auf der Partikeloberfläche führt zu der Annahme, dass N2O5 auf der Staubpartikeloberfläche zu Nitrat hydrolysiert wird. Es konnte kein Einfluss der relativen Feuchte auf den Aufnahmekoeffizienten ermittelt werden, was durch das vorhandene interlamellare Wasser, welches bis zu 10 % der Partikelmasse betragen kann, erklärbar ist. Der gemessene Wert des Aufnahmekoeffizienten ist unabhängig von der Eingangs-N2O5-Konzentration, was sich über die sehr große innere Oberfläche der Partikel erklären lässt. Dennoch ließ sich durch eine vorherige Konditionierung der Partikel mit gasförmigem HNO3, was eine Nitratanreicherung an der Oberfläche bewirkt, die Effizienz der N2O5-Aufnahme auf die Staubpartikel reduzieren. Zusätzliche Studien befassten sich mit der Bestimmung des Aufnahmekoeffizienten von N2O5 auf Illit-Partikeln und auf Teststaub aus Arizona. Bei einer relativen Luftfeuchte von 0 % wurden für γ(N2O5) Werte von 0,084 ± 0,019 (1σ) für Illit und von 0,010 ± 0,001 (1σ) für Arizona Teststaub ermittelt.rnUnter Anwendung einer neuartigen Messmethode, die auf der zeitgleichen Messung der Konzentrationsabnahme von NO3 und N2O5 relativ zueinander beruht, wurde das Verhältnis γ(NO3)/γ(N2O5) der Aufnahmekoeffizienten von NO3 und N2O5 auf Saharastaub zu 0,9 ± 0,4 (1σ) bestimmt. Dieser Wert war unabhängig von der relativen Feuchte, den NO3- und N2O5-Konzentrationen sowie der Reaktionszeit, obwohl eine Oberflächendeaktivierung für beide Spurenstoffe beobachtet wurde.